Atogepant: First Approval-Reference-Cited by-同舟云学术

Atogepant: First Approval

Published:2021-11-23 Issue:1 Volume:82 Page:65-70
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Deeks Emma D.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-021-01644-5.pdf

Reference23 articles.

1. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14.

2. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211: 107528. https://doi.org/10.1016/j.pharmthera.2020.107528.

3. Chan C, Goadsby PJ. Recent advances in pharmacotherapy for episodic migraine. CNS Drugs. 2019;33(11):1053–71.

4. AbbVie. QULIPTA (atogepant) tablets, for oral use: US prescribing information. 2021. https://www.accessdata.fda.gov. Accessed 30 Sept 2021.

5. AbbVie. FDA approves QULIPTA™ (atogepant), the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine [media release]. 28 Sept 2021. https://news.abbvie.com.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis;Expert Opinion on Drug Safety;2024-09-12

2. Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine;Expert Review of Neurotherapeutics;2024-09-12

3. A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant;Expert Opinion on Drug Safety;2024-07-08

4. An update on pharmacotherapy for trigeminal neuralgia;Expert Review of Neurotherapeutics;2024-06-13

5. The preclinical discovery and development of atogepant for migraine prophylaxis;Expert Opinion on Drug Discovery;2024-06-10